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ABSTRACT 
Question:  Breathlessness that persists despite treatment for underlying conditions is debilitating. 
Identification of this discrete entity as a clinical syndrome should raise awareness amongst patients, 
clinicians, service providers, researchers and research funders. 
Methods: Using the Delphi method, expert group consultations and one-to-one interviews (N=17) 
generated questions and statements subsequently circulated in 3 survey rounds (N= 34; N=25; N=31) 
to an extended international group from various settings (clinical and laboratory; hospital, hospice 
and community), basic sciences and clinical specialties. The a priori target agreement was 70%. 
Findings were discussed at a multi-national workshop.  
Results: The agreed term, chronic breathlessness syndrome, was defined as breathlessness that 
persists despite optimal treatment of the underlying pathophysiology and results in disability. A 
stated duration was not needed for “chronic”. Key terms for French and German translation were 
also discussed and the need for further consensus recognised, especially with regard to cultural and 
linguistic interpretation.   
Answer: We propose criteria for Chronic Breathlessness Syndrome. Recognition is an important first 
step to address the therapeutic nihilism that has pervaded this neglected symptom and could 
empower patients and caregivers, improve clinical care, focus research, and encourage wider uptake 
of available and emerging evidence-based interventions.  
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INTRODUCTION 
Breathlessness, experienced as part of everyday living, is one of the most common forms of distress, 
experienced by approximately 10% of the general population, [1] rivaling pain in prevalence 
worldwide.[2]. Like pain, breathlessness can resist treatment of identified underlying condition(s), 
but nonetheless may itself be a primary target of medical management, irrespective of causative 
disease.  In the case of pain, this situation is encompassed by the term "chronic pain syndrome".[3] 
No comparable syndrome is identified for breathlessness. The question arises whether the 
experience of breathlessness persisting despite adequate treatment of causative conditions should 
be delineated as a syndrome.  
 
A clinical syndrome (literally "a running together," from syn- "with" (see syn-) + dromos "a 
running, course"[4]) is a constellation of clinical findings caused by an underlying disease(s) that 
may or may not be accompanied by laboratory or imaging abnormalities. The clinical findings may 
constitute a range of symptoms and physical findings, or describe one symptom in a particular 
context(s) and may include response to interventions targeted at the syndrome itself. The syndrome 
should be recognisable in clinical and research settings. Examples of clinical syndromes include 
delirium and chronic pain syndrome, acute respiratory distress syndrome, obstructive sleep apnoea 
syndrome and Tourette’s. 
 
Although difficult to prove “cause and effect”, the description of a clinical syndrome has appeared to 
be associated with an increased awareness of its importance for clinicians, patients, service 
managers, commissioners, researchers and research funders. For example, since the delineation of 
the chronic pain syndrome, many health services now have chronic pain clinics and there is an 
International Society for the Study of Pain with its journal “Pain”. This Society has led the way in 
research into chronic pain leading to a greater understanding of the mechanisms and management 
of chronic pain. [3] This opened the way to develop effective interventions targeted at specific 
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pathological process(es) or symptomatic treatment, and to guide development and validation of its 
assessment/measurement.  
  
A variety of chronic medical conditions cause breathlessness as a key symptom: cardiorespiratory 
diseases, neuromuscular disorders, obesity, physical deconditioning, frailty, and cancer (respiratory 
or not). It is also a feature of several conditions where no somatic disorder can be identified such as 
chronic hyperventilation syndrome and related entities. Algorithms to guide the investigation of 
breathlessness, aid diagnosis and treatment of the underlying condition(s) are available, often 
leading to improvement of breathlessness.[5] However, despite optimal treatment of the underlying 
cause(s), breathlessness often persists at rest or on minimal exertion, worsening over time as the 
underlying cause(s) progress.[6, 7] 
 
Breathlessness leads to serious limitations and distress for patients and their families with a negative 
impact on emotional function, with resulting low mood and poor quality of life often accompanied 
by episodes of more intense breathlessness and panic.[8, 9]  Activities that healthy people take for 
granted can become challenging for people who are chronically breathless. Clinicians may not 
recognise the impact of chronic breathlessness given that people experiencing this will most often 
adjust their lifestyle to minimise the frequency and duration of more intense breathlessness.  
 
Under-reported by patients and under-recognised by clinicians who focus on the underlying 
disease(s) or only see patients when acutely unwell, chronic breathlessness remains hidden from 
view[10] despite being an independent predictor of: survival;[11-14] restricted activities of daily 
living; [12] and emergency health service use.[15, 16] The importance of ongoing breathlessness as a 
symptom is still poorly recognised despite recent calls by researchers for this to be a research 
priority for people with chronic obstructive respiratory disease (COPD)[17] and for access to tailored 
management as a human right.[18] .  
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Currently, breathlessness that persists despite optimal treatment of the underlying conditions is 
sometimes referred to as "refractory breathlessness" or “refractory dyspnea”.[19, 20]  However, this 
terminology has not been the object of a formal definition and has never been formally proposed as 
a syndrome. Furthermore, the term refractory suggests complete resistance to treatment and 
therefore fails to convey a message of recognition in order to manage at least symptomatically; 
several interventions to reduce the symptom safely irrespective of its cause are available or under 
investigation.[21-23] Recognition of breathlessness that persists in spite of optimal treatment as a 
clinical syndrome could be useful in the ways outlined above.[24]  
 
The aim of this study was to assess whether international expert consensus could be reached about:  
 i) whether such breathlessness could and should constitute a clinical syndrome; and 
ii) if so, how this syndrome should be named and defined? 
 
Methods: 
A 3-stage process was employed. The first two stages were conducted in accordance with the Delphi 
method.[25]  For stage 3, the results were presented and discussed during an international 
workshop.  
 
1. Expert group consultations and single interviews. 
International published experts in the field of breathlessness were invited to contribute to a group 
or individual consultation by Skype or telephone identified and conducted by DC and MJ (N=17).  
Delegates were invited from UK and continental Europe, USA and Australia to include a wide range 
of professional disciplines. Using snowball sampling, a non-probability sampling technique 
whereby existing participants recruit to the study from among their contacts, invitees were asked to 
identify and invite other key opinion leaders.  
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A topic guide was used to ensure each consultation included key areas but allowed other topics to 
arise. This followed a process of posing questions to generate ideas and debate, clarification and 
focus on areas of agreement and then identification of the remaining areas of debate to be further 
explored during the survey rounds. The key areas included: whether chronic breathlessness could 
and should constitute a clinical syndrome; if so, its name and definition; and the purpose that 
defining a syndrome would serve. 
 
Detailed notes of agreements and disagreements were taken contemporaneously by MJ and DC, and 
used to identify those issues where delegates had agreed and those where disagreement identified 
questions to use in the survey rounds.  
 
2. Survey rounds 
A target 70% agreement for each question was pre-specified. Three sequential survey rounds 
(responses n= 34; n=25; n=31) were individually completed using an online platform (Qualtrics 
Insight Platform, Utah, 2002). The first survey (Invitation and Survey available as online only text) 
was developed to explore views on a preliminary name and definition, as well as specific questions 
relating to each concept within the definition. The survey was sent to an extended group of experts 
(the consultation group and others) by email (n= 52) and was introduced with a summary of the 
prior iteration of agreement already reached from the expert groups after round one. In addition to 
choosing their preferred option provided for each question, each participant was invited to generate 
additional views and clarifications as supplementary free text.  
 
At the end of the first survey, respondents were asked if they were willing to participate in 
subsequent rounds. Those who agreed were sent surveys 2 and 3. Collated agreements circulated in 
successive rounds meant that responses were anonymous to other members of the group reducing 
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the risk that some may feel pressure to conform to the views of others. Survey completion was 
taken as implied consent. As a result of each survey round, the name and definition were modified 
and options narrowed as consensus developed. As part of the last survey, a summary of the free text 
comments contributed by respondents was also provided.  
 
 
3. Workshop 
The findings of the first two steps were presented and discussed at an international meeting for 
those interested in breathlessness research (Dyspnea 2016, Paris: 
http://www.dyspnea2016inparis.fr/). Specific discussions explored how such a name and definition 
would be translated usefully into different language and cultural settings. 
 
Role of the Funding source 
This unfunded study was conducted within resources. 
Ethics 
Ethical approval was not required for the Delphi process as researchers sought expert professional 
opinions only. 
 
FINDINGS: 
Group Consultations and Interviews 
Four group consultations comprising a total number of 13 participants (N = 5; N = 4; N = 2; N = 2) 
were held between 17th July and 10th August 2015 each lasting approximately one hour. In addition, 
MJ interviewed four individuals. Invitees included experts from the following disciplines: respiratory 
medicine, cardiovascular medicine, primary care, medical, nursing, respiratory physiology, 
neuroimaging, intensive care, oncology and palliative care. 
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There was agreement that the symptom of breathlessness in these clinical settings should be raised 
to a clinical syndrome in the context of: 
i. persistence of breathlessness due to a causative medical condition(s) despite 
optimal treatment for the condition(s); and 
ii.  negative consequences of the breathlessness. 
 
It was agreed that recognition of a clinical syndrome would help to address the invisibility of such 
breathlessness. Further, for people experiencing this breathlessness, participants concurred that a 
recognised syndrome would help to validate their own experiences and give permission for patients 
to discuss their ongoing breathlessness with their clinicians.  It was also felt that gaining research 
funding was rendered more difficult by a lack of recognition of chronic breathlessness by reviewers 
and research funders.  
 
Surveys 
The extended group also included occupational therapy and physiotherapy clinicians. The 
development of agreement can be seen in Table 1. All reached the pre-set target of ≥70% 
agreement, except the part of the definition relating to how the treatment of the underlying disease 
should be phrased (68%). All 35 respondents to survey 1 agreed to participate in surveys 2 and 3. A 
summary of the free text comments provided to the respondents between surveys 2 and 3 can be 
seen in eTable 1. Survey response rate was 34/52 (51%) for survey 1; 25/34 (74%) for survey 2 and 
31/34 (91%) for survey 3. 
 
<< insert Table 1 about here>> 
 
By survey 3, participants agreed that the name of the syndrome should be “chronic breathlessness 
syndrome” (77%) and should be defined as: breathlessness even though “…evidence-based 
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treatments of underlying pathophysiology of the causative disease(s) are optimised” (68%), “which 
contributes to physical limitations and/or a variety of adverse psychosocial, spiritual or other 
consequences” (77%). The term “chronic” did not need a stated duration (80%). Rather than 
continue to another round, 68% agreement for the treatment question was considered to be 
sufficient. 
 
Workshop 
Participants in the workshop agreed that chronic breathlessness should be defined as a clinical 
syndrome. It was suggested that the definition regarding the adverse consequences of chronic 
breathlessness should reflect the language of the World Health Organisation (WHO) definition of 
disability to ensure global consistency.[26] The WHO International Classification of Functioning, 
Disability and Health (ICF)[26] defines disability as an overarching term for the interaction between 
individuals with a health condition (e.g. COPD) and personal and environmental factors (e.g. 
negative attitudes, inaccessible transportation and public buildings, or limited social supports).  
 
There was extended and useful discussion about the trans-national translation of the name and 
definition of the syndrome particularly from the participants from the United Kingdom, Australia, 
France and America.  For example the term “dyspnea” was more familiar to American delegates, but 
it was recognized that the lay term, “breathlessness”, should be used.  The other contender was 
“short of breath”, but, on balance, it was felt that the addition of “chronic” made it clear that the 
syndrome referred to troublesome breathlessness. German attendees felt that no additional words 
to define breathlessness were needed; “refractory” would be unhelpful in German, giving the sense 
of “no hope”, and “short of breath” had a particular meaning which was inappropriate. For Swedish 
participants, it was felt that “chronic breathlessness “was acceptable”. In French, an adjective was 
thought to be needed and the term "persistante" in addition to, or in place of, "chronic". Although 
the English speakers felt that "chronic" implicitly contained the notion of “pathological”, this was not 
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the case for French speakers. There was concern about the term "dyspnée" because the lay term 
"essoufflement" (exact French translation of "breathlessness") encompasses both "worrying" and 
"non-worrying" situations (as in being "out of breath" -essoufflé- after acute exertion). However, 
"essoufflement persistant" or "essoufflement chronique persistant" could be discussed.  
It was decided that a specific project aiming at providing the best French translation of "Chronic 
breathlessness syndrome" could be conducted secondarily by the Dyspnea working group of the 
French learned society for respiratory medicine (Société de Pneumologie de Langue Française). 
It is hoped that this start toward some international consensus will stimulate further debate and 
discussion including translation into other languages and cultures.  
 
DISCUSSION. 
Using the Delphi method enhanced by an extended discussion among participants at an 
international meeting of experts on breathlessness, we attained broad consensus on the utility of 
recognizing a distinct clinical entity that can be named “Chronic Breathlessness Syndrome”. We 
define this syndrome as the experience of breathlessness that persists despite optimal treatment of 
the underlying pathophysiology and results in disability for the patient. Participants decided that a 
descriptor such as “refractory” was not needed (and indeed, was considered unhelpful by some) in 
the title or in the definition. 
A pathophysiological basis is not required in order to delineate a clinical syndrome.  However, there 
is emerging evidence suggesting that the perception of chronic breathlessness in patients and acute 
breathlessness induced in healthy volunteers differ in some respects although they share common 
pathways.  Neuroimaging studies indicate that people living with chronic breathlessness may have a 
higher level of breathlessness “vigilance” even when comfortable at rest compared with healthy 
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volunteers [27] and central perception of chronic breathlessness due to COPD involves activation of 
the frontal associative cortex (fear and memory) not seen in healthy volunteers. [28] Further, people 
with COPD have a higher neural respiratory drive at rest than healthy volunteers. [29][30] Neural 
respiratory drive closely correlates with breathlessness intensity and has been suggested as a 
biomarker for chronic breathlessness.[30] 
The personal, behavioural and social adjustments in patients with chronic breathlessness are clearly 
of a different kind and order than those experiencing acute, episodic breathlessness. In addition, the 
clinically important difference for breathlessness intensity is smaller for chronic breathlessness (1 
point change in 0-10 numerical rating scale, compared with 2 point change for acute 
breathlessness). [20, 31].  The experiences are different, and thus benefit is likely to be perceived 
differently.   A change of 2 points may be needed to reassure the distressed, terrified person with 
acute, episodic breathlessness that they are not going to die. Conversely an improvement of 1 point 
for the person living with chronic breathlessness as a daily limitation may mean that they are able to 
make their own cup of tea, or manage to the toilet on their own.  
 
Implications for clinical practice and policy 
Widespread opinion from a variety of specialties and professions was sought so that the proposed 
definition, with its common language, would be broadly relevant across research methods and 
clinical practices as well as to patients living with chronic medical conditions leading to chronic 
breathlessness. Whereas it is good clinical practice to seek out and assess a symptom systematically, 
this is not routine in many settings where the focus is optimising the underlying disease treatments. 
Systematic documentation of chronic breathlessness in healthcare settings alone is unlikely to be 
sufficient to alter practice in the context described here, and from work in pain, assessment alone is 
unlikely to improve symptom control.[32] The delineation of chronic breathlessness syndrome 
provides focus for directed systematic clinical enquiry including targeted intervention. Usual practice 
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often stops at the point of optimised treatment of the underlying disease(s) (“nothing more we can 
do”). However, there are non- pharmacological and pharmacological evidence-based interventions 
for chronic breathlessness as a therapeutic target,[21, 23, 33-37] but these remain underused in 
clinical practice.  Routine assessment will increasingly help to standardise the timely use of these 
treatments and foster a robust multi-disciplinary team approach whereby patients are referred 
routinely for active management of breathlessness by respiratory physiotherapists and psychologists 
and considered systematically for regular, low dose oral extended release morphine. We cannot 
guarantee that the recognition of this syndrome will change clinical practice and clinical outcomes, 
however, without its recognition we will not see progress and patients will not derive the benefit 
they deserve.   
Education about these interventions is crucial as clinicians may be reluctant to look for something 
they believe they cannot treat. With regards to service provision, the identification of chronic 
breathlessness syndrome may result in evidence-based breathlessness services becoming the 
standard of care. Multi-disciplinary and multi-speciality breathlessness services are already 
developing, (e.g., pulmonary and cardiology) albeit with a focus on diagnosis. A next step could be 
for such specialised clinics to expand their scope to research and practice of breathlessness 
palliation.  
Although much of the literature relating to the management of the symptom of breathlessness has 
come from palliative care to date, this clinical presentation is seen by family medicine/general 
practice, respiratory medicine, cardiology, geriatrics and palliative care. Therefore, the responsibility 
to address the chronic breathlessness syndrome is one that must be shared by the medical 
community as a whole.  
The overt recognition of chronic breathlessness syndrome will empower patients and their 
caregivers to more easily raise their symptom burden in clinical consultations, rather than suffering 
in silence. Likewise, ensuring that the community more broadly is aware of the syndrome will 
facilitate conversations to drive better care.  
The syndrome of chronic pain provides a useful parallel in some aspects. Recognition that chronic 
pain is a different entity to acute pain and thus should be managed differently [3] was pivotal in 
improving understanding, management and service provision of this common and difficult condition. 
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The devastating impact on psycho-social function with resultant disability, often caught up in a 
deteriorating cycle of unhelpful adaptation to the symptom by reducing activity is common to both. 
An understanding of this has informed the multi-disciplinary nature of chronic pain clinics with an 
emphasis on physiotherapy and psychological approaches to management and appears pertinent to 
chronic breathlessness. Likewise, the more recently proposed clinical entity, “dyspnea crisis” [38] is 
highly pertinent to this discussion in that crisis often occurs on a background of chronic 
breathlessness. There are notable differences, however, in that “chronic pain syndrome” includes a 
plethora of subtypes described in a complex taxonomy,[39] and unlike severe breathlessness, the 
experience of chronic pain is rarely associated with a fear of imminent death. 
There may be concerns that recognition of chronic breathlessness as a syndrome may lead to 
inappropriate and excessive prescribing of opioids, particularly for patients who may be vulnerable 
to overdose such as patents with advanced COPD.[34, 40] We suggest that a chronic breathlessness 
syndrome would stimulate a posology of opioid prescription based on evidence-based effectiveness 
and safety data rather than the current variations in practices, including inadequately evaluated 
regimens.  This which would allow greater net benefit and place pharmacological treatment within a 
step-wise approach to management founded on non-pharmacological management.[41]  
 
Implications for research 
Chronic breathlessness syndrome will create a common language between and within groups of 
researchers. More consistent descriptions of study populations will help application of findings. A 
distinct entity which stimulates a structured and mechanistic approach should also help target 
research priorities towards further understanding of the pathophysiology of chronic breathlessness, 
identification of further potential therapeutic targets and optimal service delivery models. 
Recognition of chronic breathlessness syndrome could also create a profile for potential funders.  
Importantly, the involvement of patients and family caregivers in the development of consensus can 
now be addressed given the frame which this initial work provides. 
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Strengths and limitations 
This paper deliberately sought the views of opinion leaders, that is, members of the community of 
clinicians and researchers who are influential not because they have opinions, but because their 
opinions are sought after and published. The opinions of this wide range of respondents from 
around the world were successfully synthesised into a definition that could be used in a number of 
other languages. This definition spans people working in the basic sciences as well as a variety of 
clinical specialities.  
The limitations are those that are inherent to Delphi processes. Not all respondents competed all 
surveys, but the response rate for surveys 2 and 3 was good. There was no clear pattern in the non-
respondents in the first survey. Given the broad nature of the professional background of 
participants, a slightly lower a priori agreement threshold of 70% was set. However, one question 
failed to reach this, and most gained more than a more usual agreement of 75%. There may be 
concerns that a Delphi method is open to a bias towards inclusion of only like-minded experts. 
However, there was vigorous debate throughout the survey rounds, nearly requiring a 4th survey. 
Further, the Paris Dyspnea 2016 workshop was not part of the Delphi process.  It was attended by 
people who were independent from it and who were unaware that this would be on the agenda in 
this manner; they were not hand-picked.  
Inherent with the methodology, the number of participants is limited. Therefore, the respondents’ 
views cannot be fully representative of all concerned. We expect that this proposition of "chronic 
breathlessness syndrome" will generate reactions and debate and we acknowledge that this term 
may evolve as a result. Linguistic and cultural specificities may lead to variations around the world 
and there may be further discussion on how the chosen terminology applies to certain clinical 
situations. For example, a participant in the Dyspnea 2016 workshop, noted that "breathlessness 
that persists in spite of optimal treatment of the underlying conditions" is frequently experienced by 
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critically ill patients receiving prolonged mechanical ventilation.[42] However, in this setting, the 
word "chronic" may not be relevant to intensivists to characterize the corresponding category of 
patients, and could be replaced by "persistent". The very fact that questions and debates will arise in 
reaction to the present proposition should be considered as a first marker of its relevance.  
 
CONCLUSIONS 
We propose chronic breathlessness syndrome as a framework for further discussion. Whatever the 
name (or names) agreed finally and recognised globally, such recognition of a distinct clinical 
syndrome is likely to improve clinical care, focus research and, ultimately, reduce suffering through 
empowering patients and their caregivers. Additional development is warranted, including 
engagement of patients and family caregivers to refine understanding and application. Using the 
syndrome as the basis for wider use of evidence-based interventions is an important first step to 
address the therapeutic nihilism that has pervaded this area of practice.  
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Table 1. Development of agreement over successive surveys. 
Survey*  Survey 1* N= 35 Survey 2* N = 27 Survey 3* N = 31 
Name of 
syndrome 
 “chronic” 67%  
“chronic” only needed 15% 
“refractory” 58% 
“persistent”…48% 
“intractable”…3% 
”intolerable”…3% 
Chronic breathlessness 26% 
Chronic refractory breathlessness 
60% 
Chronic persistent breathlessness 
14% 
Chronic breathlessness 77% 
Chronic refractory breathlessness 
23% 
 
Definition 
Chronic “if using chronic or 
persistent, this should be 
individually assessed and 
not further defined.”80% 
1 month/3 month/from 
this point 20% 
  
Treatment of 
underlying 
disease 
 “Treatment of underlying 
medical disease(s) is 
optimised” 63% 
 “The underlying medical 
disease(s) is receiving best 
possible treatment” 31% 
no preference 6% 
Treatment of underlying  
pathophysiology is optimised 41% 
The patient is receiving optimal 
evidence based treatment for the 
underlying pathophysiology 59% 
Treatment of underlying 
pathophysiology is optimised 32% 
Evidence-based treatment of 
underlying pathophysiology is 
optimised 68% 
Negative 
consequences 
of 
breathlessness 
“None of the above* are 
needed for the definition” 
55% 
 “Significant physical 
limitations” 33% 
 “Anxiety” 6% 
”deconditioning”3% 
None needed 37% 
...[breathlessness]contributing to 
physical limitations and/or a 
variety of adverse psychosocial, 
spiritual or other consequences 
59.3% 
...[breathlessness]contributing to 
physical Limitations 3.7% 
None needed for the definition 
23% 
...[breathlessness]contributing to 
physical limitations and/or a 
variety of adverse psychosocial, 
spiritual or other consequences 
77% 
*see survey in Appendix 1 for the detail 
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eSURVEY AND INVITATION 
 
Dear <<name>>, 
 
We are pleased to invite you to participate in a Delphi survey to see if we can produce an agreed 
name and definition of a new clinical syndrome of chronic breathlessness caused by medical 
conditions. 
 
The survey should take 5 minutes to complete. 
 
A clinical syndrome is a constellation of clinical findings caused by an underlying disease(s). The 
clinical findings may constitute a range of symptoms and physical findings, or describe one symptom 
in a particular context(s) and may include response to interventions targeted at the syndrome itself. 
The syndrome should be recognisable in the clinical and research settings. Examples of clinical 
syndromes include heart failure, delirium, sepsis, parkinsonism and chronic pain. 
 
During July and August 2015, experts from the following disciplines: respiratory medicine, 
cardiovascular medicine, primary care, medical, nursing, respiratory physiology, neuroimaging, 
intensive care, oncology and palliative care were consulted. 
 
There was agreement that the symptom of breathlessness could be raised to a clinical syndrome of 
chronic refractory breathlessness if the breathlessness: 
• due to a causative medical condition(s) persists despite treatment for that condition; 
• leads to negative consequences for the patient; and 
• responds to interventions aimed at the breathlessness. 
 
There was also consensus that recognition of a clinical syndrome would influence clinical practice, 
service provision and policy, researchers and research funding.   
 
However, although suggestions for the name and definition were generated, it was agreed that 
wider consultation through Delphi survey rounds would be important. 
 
If you could take a few minutes of your time to complete the following survey questions (by clicking 
on the link below).  Please also indicate if you would be willing to take part in subsequent rounds. 
 
 
 
 
 
SURVEY 
NAME OF SYNDROME 
A1. The following relates to the name. Show the name you feel would best identify the 
syndrome to both lay and professional audiences.  
Do you want to describe it as: (indicate one response from each of the two columns)   
 
Chronic   intractable    breathlessness  syndrome 
Persistent  refractory  
Refractory  persistent 
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intractable  chronic   
Descriptor not needed Descriptor not needed  
Other………….  Other ………. 
 
Please add any comments: 
 
 
 
A2. With regard to the timescale of the breathlessness, please indicate the one descriptor that 
should be used. 
a. If using ‘chronic’ or ‘persistent’, this should be individually assessed and not further defined 
 
b. If ‘chronic’, should this refer to breathlessness which: 
a. Will be chronic from this point forward 
b. Has been present for 1 month 
c. Has been present for 3 months 
d. Has been present for 6 months 
e. Has been present for 12 months 
 
c. If persistent, should this refer to breathlessness which: 
a. Will be persistent from this point forward 
b. Has been present for 1 month 
c. Has been present for 3 months 
d. Has been present for 6 months 
e. Has been present for 12 months 
Please add any comments: 
 
 
DEFINITION OF SYNDROME 
The following relate to the definition.  
During consultation, it was agreed that the symptom of breathlessness could be raised to a clinical 
syndrome if the breathlessness remained a problem despite treatment for that condition and 
resulted in negative consequences for the patient. 
 
Please underline the statement which best describes the treatment of the underlying disease. 
a. Treatment of underlying medical disease(s) is optimised 
b. The underlying medical disease(s) is receiving best possible treatment  
c. No preference 
Please add any comments: 
 
 
B3. With regard to negative consequences of the breathlessness, please indicate any which should 
be explicitly included in the definition: 
a. Significant physical limitations 
b. Deconditioning 
c. Social isolation 
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d. Depression 
e. Anxiety 
f. Financial concerns 
g. Spiritual distress 
h. Health service utilisation 
i. Unscheduled health service utilisation 
j. None of the above are needed for the definition 
Please add any comments: 
 
 
 
Thank you very much for your help. Please indicate here if you would be happy to receive the next 
Delphi survey round. 
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eTable 1. Summary of freetext comments circulated with survey 3 
 
 
1. Name. The main area of disagreement related to whether a descriptive word e.g. “refractory” should be 
part of the NAME, or only used in the DEFINITION.  
• The term “refractory” carries the implication that there's no point in doing anything about it as it won't 
respond to therapy – which is not what we are trying to convey with the name of this syndrome. It risks 
being misunderstood by clinicians, patients and the lay public. 
• The word refractory is particularly misleading for German speakers. 
• A change of "chronic breathlessness" to "refractory breathlessness" would need education through under 
and post graduate training for nurses and doctors. 
• Keep the name simple. Chronic Breathlessness Syndrome implies that breathlessness persists despite 
treatment of the underlying cause.    We don’t say "Chronic Persistent Bronchitis," or "Chronic Intractable 
Pain Syndrome" 
• Chronic has the same acceptable meaning as persistent or "always there" and therefore you don't need 
two words in the definition that commonly mean the same thing.    
• You don’t need refractory in the title of the syndrome, but it does need to be defined in the detail. 
 
2. Treatment.  
• The definition refers to breathlessness which persists despite treatment directed at the underlying disease 
pathophysiology, rather than its effects or symptoms. That is –  “despite disease treatments” – rather than 
“despite breathlessness treatments” . Other comments are included below: 
• optimal suggests that it is evidence based without the need for this qualification. 
• optimal "evidence-based" is important to state, otherwise the treatment utilized could be suboptimal 
• This 'syndrome' would help identify patients with COPD/CHF/ etc who despite pharmacological therapy are 
still breathless (where the mechanisms: deconditioning, anxiety and depression, dysfunctional breathing 
are similar). This would help identify patients that would benefit from a generic 'breathlessness' approach.  
• … pulmonary rehabilitation can, for example, be included as an option as treatment for Chronic 
Breathlessness Syndrome caused by a chronic lung disease 
 
3. Consequences.  
• There are so many, that listing becomes too complicated, could just have a “catch all” of “negative 
consequences regarding the physical, psychological, social and spiritual dimension”.  
•  Consequences are individual to the person, but given the characteristics defined by your original panel of 
experts, some acknowledgement of consequences in the definition should be included.     
• These are "correlates" or "covariates" - they vary or change because of the phenomenon (symptom) of 
chronic breathlessness -…they are conceptually outside the phenomenon- not the phenomenon itself.  If 
included in the definition it will be conceptually incorrect. 
• In order to be a syndrome, I think that it needs to have any negative abnormal consequence. 
Breathlessness is normal during certain levels of exertion. Some could say that "chronic" would separate 
normal from abnormal breathlessness but that word can be understood in many ways.  
• Description of negative consequences helps to de-medicalise the definition and identifies the illness 
experience. Both are important to include. 
• Think these are helpful for people who are not specialist yet 
• Not all limitations are physical, but they can be just as devastating! 
